33 results about "Endotoxin shock" patented technology

The invention relates to a novel strain, Lactobacillus fermentum strain, and a use thereof. Specifically, novel Lactobacillus fermentum PL9988, novel Lactobacillus fermentum PL9037, novel Lactobacillus fermentum PL9038, novel Lactobacillus fermentum PL9039 and novel Lactobacillus fermentum PL9040 strains, isolated from adults in a longevity village, and culture fluids thereof: have no antibiotic resistance transfer; have excellent intestinal cell adhesiveness, acid resistance and bile resistance; inhibit harmful pathogenic organisms in intestines; and have an immunity-enhancing effect, an endotoxin shock suppression effect and an antioxidant effect. In particular, Lactobacillus fermentum PL9988 strain significantly satisfies all of the above-mentioned conditions as a probiotic, and thus can be effectively used as a probiotic for intestinal health and defecation improvement and enhancement, or as a health food.

The invention relates to tumor necrosis factor-alpha polypeptide inhibitors and application thereof. The invention relates to the field of medicine, and particularly relates to polypeptides capable of inhibiting matrix metal proteinase-2 and tumor necrosis factor liberase and relieving damage of acute inflammation response on organisms. The sequence of the polypeptide is Pro-Thr-Thr-Asn-Arg which is a brand-new sequence. The inhibitors can inhibit the activities of the matrix metal proteinase-2 and tumor necrosis factor liberase in vitro on the 1 micromole level, and increase the survival rate of endotoxin shock mice in an in-vivo test, thereby having potential new drug development value.

The present invention relates to one kind of Chinese medicine composition for treating endotoxemia and its preparation process. The Chinese medicine composition consists of effective components prepared with capillary artemisia, cape jasmine, rhubarb, red sage, honeysuckle and other five kinds of Chinese medicinal materials in certain weight proportion, and pharmaceutically acceptable carrier. TheChinese medicine composition is used in treating endotoxemia and various diseases with endotoxemia complication, and has especially high curative effect on endotoxin induced endotoxin shock and multiple organ incompetence.

The invention relates to a preparation method of the antipyretic and antiviral active part of the traditional Chinese medicine compound Reduning injection and its application in the preparation of antiviral medicine or antipyretic medicine. The preparation method disclosed by the invention adopts macroporous adsorption resin column chromatographic separation technology; and uses various chemical component separation methods and modern spectroscopic analysis means to separate and identify the chemical components of the active part. The active part in the present invention can significantly prolong the survival time of the stress mice infected with the influenza A (H1N1) FMI strain in vivo, reduce the death rate of the mice, and have a good antipyretic effect on the fever of the endotoxin shock mice induced by LPS. Therefore, Reduning injection and its active parts have good antipyretic and antiviral effects.

The invention discloses the application of mycoepoxydiene nicotinic acids derivatives in the preparation process of pro-inflammatory mediator inhibitors, and relates to the mycoepoxydiene nicotinic acids derivatives 4-NDM (4-N Dodecyl Mercaptan). The provided application of the mycoepoxydiene nicotinic acids derivatives in the preparation process of the pro-inflammatory mediator inhibitors particularly relates to the application of the mycoepoxydiene nicotinic acids derivatives in the preparation process of drugs that are used for treating inflammatory diseases such as endotoxin shocks which are mediated by inflammatory factors. The molecular formula of the mycoepoxydiene nicotinic acids derivatives is C19H19NO4. Pharmacology experiments prove that the mycoepoxydiene nicotinic acids derivatives can effectively inhibit the expression of the inflammatory factors such as tumor necrosis factor (TNF-Alpha), interleukin 6 (IL-6) and nitric monoxide (NO). The mycoepoxydiene nicotinic acids derivatives can be used for preparing the pro-inflammatory mediator inhibitors, especially, the mycoepoxydiene nicotinic acids derivatives can be used for preparing the drugs for treating inflammatory diseases such as endotoxin shocks which are mediated by inflammatory factors.

The invention relates to the field of medicine, and particularly relates to polypeptides capable of inhibiting matrix metal proteinase-2 and tumor necrosis factor liberase and relieving damage of acute inflammation response on organisms. The sequence of the polypeptide is Pro-Thr-Thr-Asn-Arg which is a brand-new sequence. The inhibitors can inhibit the activities of the matrix metal proteinase-2 and tumor necrosis factor liberase in vitro on the 1 micromole level, and increase the survival rate of endotoxin shock mice in an in-vivo test, thereby having potential new drug development value.

The matrix metal protease-2 polypeptide inhibitor and its application.The invention involves the field of drugs, which specifically involves a polypeptide that has the inhibitory metal protease-2 and tumor necrosis factor release enzymes, and a reaction to the destruction of acute inflammation.Its sequence is iL-Ser-Glu-CYS-MET-Ser. They can in vitro in vitro-2 and tumor necrotic factors at the level of 1 microore.Increase the survival rate of internal toxin shock mice, and has potential new drug development value.

The present invention provides the application of icariin in the preparation, treatment or prevention of damage caused by bacterial infection, and specifically relates to its application in the prevention or treatment of sepsis, endotoxemia and endotoxin shock caused by damage caused by bacterial infection . The invention also relates to its application in medicines for enhancing the curative effect of antibiotics.

The invention relates to the field of drugs and particularly relates to a polypeptide capable of activating natural killer T cells, inhibiting matrix metalloproteinases-9 and relieving destruction of acute inflammatory reaction to an organism. The polypeptide has the sequence as follows: VVHPLSSARWGGRR which is a brand new sequence. The polypeptide can be used for inhibiting the activity of matrix metalloproteinases-2 in vitro on the level of 1 micromole and increasing the survival rate of endotoxin shock rats in an in-vivo test so as to have a potential novel drug development value.

The invention discloses application of epoxydiene taken as an inhibitor of proinflammatory mediators, and relates to a compound, namely the epoxydiene, in particular to application of the epoxydiene taken as the inhibitor of the proinflammatory mediators in medical field. The invention provides the application of the epoxydiene taken as the inhibitor of the proinflammatory mediators, in particular application in preparing a medicament for treating inflammatory diseases mediated by the proinflammatory mediators such as endotoxin shock and the like, and application in preparing a medicament fortreating inflammatory diseases mediated by the proinflammatory mediators such as rheumatoid arthritis and the like. A pharmacological experiment proves that the epoxydiene has important adjustment effect on the processes of inflammations by inhibiting the expression of a plurality of the proinflammatory mediators, and can be used for preparing anti-inflammatory medicaments. The compound can be obtained by separating from fungus fermentation products, and can also be chemically synthesized.

The invention relates to sense oligonucleotide having a sequence complementary to a single-stranded RNA (antisense transcript) having a sequence complementary to mRNA of iNOS gene in order to control expression of iNOS (inducible nitric oxide synthase). The sense oligonucleotide of the present invention can control expression of iNOS and is useful for biological defense and treatment and prevention of diseases related to excessive production of NO, such as cancerogenesis, inflammatory disease, endotoxin shock by bacterial infection and the like.

Matrix metalloproteinase-2 polypeptide inhibitors and applications thereof. The invention relates to the field of medicine, in particular to a polypeptide capable of inhibiting matrix metalloproteinase-2 and tumor necrosis factor-releasing enzyme and reducing acute inflammatory response damage to the body. Its sequence is Asp-Asn-Phe-Ser-His-Thr, which is a brand new sequence. They can inhibit the activity of matrix metalloproteinase-2 and tumor necrosis factor releasing enzyme in vitro at the level of 1 micromolar, and increase the activity of endogenous enzymes in vivo. The survival rate of mice in toxin shock has potential value for new drug development.